BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
← catalyst calendarNCT03474770 · readout in 133 d
Sponsored by Supernus Pharmaceuticals, Inc. (industry) · SUPN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
16estimated
Sites
2
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-04-10 | actual | When the study began enrolling |
| Primary completion | 2026-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2018-03-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2022-08-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Focal Impaired Awareness Seizures
Intervention
- Drug: BIS-001ER — also filed as Huperzine A ER
Primary outcome
what the primary-completion date above is the date OFEffect of BIS-001ER on Seizure Count
measured 6 Weeks
Permalink · SUPN's whole pipeline · Catalyst calendar · Every registered study · What changed